Date: 2017-02-07
Type of information: IPO
Company: Lysogene (France)
Investors: Sofinnova Partners (France) BpiFrance (France) Novo A/S (Denmark) Financière Arbevel (France) Alto Invest (France)
Amount: € 22.6 million
Funding type: IPO
Planned used: This IPO will provide Lysogene with additional financial resources to fund its activities and pursue the development of its technology platforms and drug candidates. The proceeds of the Offering will mainly finance the completion of the pivotal study in Europe and the United States of LYS-SAF302, for the treatment of mucopolysaccharidosis IIIA, with up to two-thirds of the net proceeds of the offering, the completion of the phase I/II study of LYS-GM101 for the treatment of GM1 gangliosidosis, with up to approximately one-fourth of the net proceeds of the Offering.
The remainder of the net proceeds of the Offering (one-twelfth) will finance the company's continuing activities aside from the foregoing two R&D programs.
Others: * On February 7, 2017, Lysogene announced its successful initial public offering on Compartment C on Euronext Paris by way of an open price offering and a global placement, raising €22.6 m by means of a capital increase. Sofinnova Partners, BpiFrance Investissement (InnoBio) and Novo A/S participated in the offering with € 15 million and new partners such as Financière Arbevel with € 2 million and Alto Invest have joined Lysogene during this IPO. The price of the OPO and the Global Placement is €6.80 per share corresponding to the low-range price of the Offering. 3,323,567 new shares will be issued in the context of the Offering, allowing for a capital increase of €22,600,256 (including issuance premium), up to approximately 89% of the initially envisaged capital increase without the overallotment option. On the basis of a price per share of €6.80, Lysogene's market capitalisation is approximately €82.1 following the transaction.
Therapeutic area: Rare diseases - Genetic diseases
